正在加载公司
Just reported
Q3 2026 results
From OPKO Health's results release of 2026年11月4日; its quarterly report has since been filed.
Revenue
Actual
US$65.4M
+16% y/y
-60% q/qGuided
—
No guide given
EPS, GAAP
Actual
-US$0.07
Guided
—
No guide given
Operating income, GAAP
Actual
-US$31.4M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes OPKO Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.US$259.4BA+
IDXXIdexx Laboratories Inc.US$55.5BA+
IQVIQVIA Holdings Inc.US$43.7BA
ILMNIllumina, Inc.US$31.3BA+
LHLabcorp Holdings Inc.US$30.1BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
基于 OPKO Health, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
